Venus Remedies Q1 net profit more than doubles to ₹25.53 cr
Standalone revenue rose 30% to ₹178.80 cr from ₹137.13 cr a year ago. EBITDA jumped to ₹39.11 cr. Board approved technical MoA alteration.
— 5 earlier stories on Venus Remedies Ltd. →What's new
- Revenue up 30% to ₹178.80 cr; net profit more than doubled to ₹25.53 cr.
- EBITDA rose to ₹39.11 cr from ₹20.66 cr.
- Board approved revised draft MoA alterations; pharma operations unchanged.
Why this matters
Profit doubling on 30% top-line growth signals strong profitability gains. Zero debt and a trailing ROE of 8.1% suggest room for higher returns if this trajectory holds. The MoA tweak is housekeeping, not a strategic shift.
What we're watching
- Whether profit momentum sustains through H2 FY27.
- Any new product launches or export orders that could expand revenue.
- Q2 commentary on raw material costs and pricing.
The full read
Venus Remedies delivered a strong June quarter. Revenue hit ₹178.80 cr, up 30% from a year ago, but the real story is the bottom line: net profit more than doubled to ₹25.53 cr and EBITDA nearly doubled to ₹39.11 cr. That profitability improvement came as revenue grew faster than costs. The company also flagged a memorandum amendment, but the principal pharma business is unchanged: a clean-up, not a pivot. With zero debt and a trailing ROE of 8.1%, there is room for higher returns if this margin holds. A routine quarterly filing, but the numbers speak for themselves.
Questions answered
- How much did net profit grow in Q1?
- Net profit more than doubled to ₹25.53 crore from ₹11.70 crore a year earlier.
- What was the revenue growth?
- Revenue grew 30% to ₹178.80 crore from ₹137.13 crore in the year-ago quarter.
- What is the MoA alteration about?
- The board approved revised draft alterations to the memorandum of association to update the objects clause. The company says its principal pharmaceutical operations remain unchanged.
- Does Venus Remedies have debt?
- As per latest available data, the company has zero debt (debt/equity 0.00).
Venus Remedies Ltd.
Latest quarter · Jun 2026
Strength & growth
Story so far
All notes on VENUSREM →- 20 Jul 2026 · 6:43 PM IST Venus Remedies Q1 net profit more than doubles to ₹25.53 cr
- 8d ago Venus Remedies Q1 profit more than doubles on 30% revenue jump
- 63d ago Venus Remedies reports audited results and declares dividend
- 63d ago Venus Remedies posts 89% profit jump and names new board members
- 63d ago Venus Remedies profit jumps 89% as annual revenue hits ₹768.7 cr